Search results for " recombinant"
Article
Antibody Production in Microbial Hosts
With more than 200 recombinant proteins on the market today, the biopharmaceutical industry is expected to reach approximately $180 billion by 2016 (1). Therapeutic mAbs and their derivatives—such as …
Article
Ensuring the Quality of Biologicals
Biologicals are those products derived from biological sources such as tissues and cell extracts, fermentation using micro-organisms, plasma, plants, or those produced by recombinant DNA technology. T…
Article
A Closer Look at Affinity Ligands
Today, Protein A ligand is manufactured and purified on a large scale using recombinant DNA technology. Purfied Protein A ligand is covalently coupled (conjugated) to a solid, porous support to form a…
Article
FAQs about Cytiva™ Protein Select™ technology
This FAQ page provides answers to a range of questions covering the mechanism, application, capabilities, and potential use cases of the resin and tag for purifying recombinant proteins.
Explore qu…
Article
Recent Advances in the Use of Exoglycosidases to Improve Structural Profiling of N-glycans from Biologic Drugs
Recently, New England Biolabs, a provider of recombinant and native enzymes for molecular biology applications, completed an effort to redesign manufacturing of the most widely used analytical glycosi…
Article
Fifteen Years of Progress: Biopharmaceutical Industry Survey Results
Also, during this period, the number of FDA-approved recombinant therapeutics has increased by approximately 400% (6,7). In 2017, FDA set a record for the number (31 approvals) and percent (93%) of ap…
Article
Automation Trend in Fill/Finish Reduces Contamination Risk
The company installed the new filling line to meet demand for innovative biologics, including vaccines, gene therapies, oncolytic live virus-based therapies, monoclonal antibodies, and recombinant pro…
Article
Unifying Continuous Biomanufacturing Operations
“Typically, in antibody and most recombinant protein production, cell lines are very stable. Certain exceptions exist, and certainly, a few companies have published on enzyme-producing cell lines that…
Article
Downstream Processing for Cell-Based Therapies
In most cases, the process is likely to involve the use of an animal-free recombinant enzymatic dissociation reagent (such as recombinant trypsin) and some physical force exerted through an increase i…
Article
Continuous Processing for the Production of Biopharmaceuticals
In recent years, there have been publications reporting development of a fully integrated end-to-end commercial continuous process for the manufacturing of recombinant monoclonal antibodies (5).
T…